EA201991069A1 - Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом - Google Patents

Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом

Info

Publication number
EA201991069A1
EA201991069A1 EA201991069A EA201991069A EA201991069A1 EA 201991069 A1 EA201991069 A1 EA 201991069A1 EA 201991069 A EA201991069 A EA 201991069A EA 201991069 A EA201991069 A EA 201991069A EA 201991069 A1 EA201991069 A1 EA 201991069A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
phosphoinositide
kinase
pharmaceutically acceptable
combined therapy
Prior art date
Application number
EA201991069A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991069A1 publication Critical patent/EA201991069A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

В изобретении предложен способ лечения рака у субъекта, который в этом нуждается, включающий введение субъекту (a) соединения формулы Iили его фармацевтически приемлемой соли, где R представляет собой водород или ацильную группу; и (b) ингибитора BCL-2; причем соединение формулы I или его фармацевтически приемлемая соль и ингибитор BCL-2 вводят в количествах, которые в комбинации являются терапевтически эффективными. Кроме того, в изобретении предложена фармацевтическая композиция, содержащая соединение формулы I или его фармацевтически приемлемую соль, ингибитор BCL-2 и фармацевтически приемлемый носитель или вспомогательное вещество.
EA201991069A 2016-11-02 2017-11-01 Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом EA201991069A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416329P 2016-11-02 2016-11-02
PCT/US2017/059464 WO2018085342A1 (en) 2016-11-02 2017-11-01 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
EA201991069A1 true EA201991069A1 (ru) 2019-10-31

Family

ID=62076339

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991069A EA201991069A1 (ru) 2016-11-02 2017-11-01 Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом

Country Status (15)

Country Link
US (1) US20180133223A1 (ru)
EP (1) EP3535272A4 (ru)
JP (1) JP2020500175A (ru)
KR (1) KR20190077040A (ru)
CN (1) CN109923117A (ru)
AU (2) AU2017355385A1 (ru)
BR (1) BR112019008698A2 (ru)
CA (1) CA3040727A1 (ru)
EA (1) EA201991069A1 (ru)
IL (1) IL266135A (ru)
MA (1) MA46728A (ru)
MX (1) MX2019004842A (ru)
PH (1) PH12019500858A1 (ru)
SG (1) SG11201903723RA (ru)
WO (1) WO2018085342A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3111938T1 (sl) 2011-04-01 2019-08-30 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN112778212B (zh) * 2021-01-28 2022-03-15 苏州莱克施德药业有限公司 库潘尼西中间体2-胺基嘧啶-5-羧酸甲酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152188A1 (en) * 2005-08-05 2010-06-17 Akella Satya Surya Visweswara Srinivas Novel Heterocyclic Compounds
JP5284977B2 (ja) * 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
SI3111938T1 (sl) * 2011-04-01 2019-08-30 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MX349551B (es) * 2012-10-10 2017-08-02 Hoffmann La Roche Proceso para preparar compuestos tienopirimidinas.
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
US20150320755A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
AU2020227036A1 (en) 2020-09-17
KR20190077040A (ko) 2019-07-02
WO2018085342A1 (en) 2018-05-11
CA3040727A1 (en) 2018-05-11
US20180133223A1 (en) 2018-05-17
PH12019500858A1 (en) 2019-12-02
EP3535272A4 (en) 2020-06-17
IL266135A (en) 2019-06-30
EP3535272A1 (en) 2019-09-11
MX2019004842A (es) 2019-06-20
SG11201903723RA (en) 2019-05-30
CN109923117A (zh) 2019-06-21
BR112019008698A2 (pt) 2019-07-16
AU2017355385A1 (en) 2019-05-30
MA46728A (fr) 2019-09-11
JP2020500175A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
PH12016502355B1 (en) Pharmaceutical composition
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA202190749A1 (ru) Способы комбинированной терапии
TW201613578A (en) Pharmaceutical combinations
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
PH12020500666A1 (en) Pladienolide compounds and their use
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12021550471A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202190125A1 (ru) ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
NZ757538A (en) Reducing beta-catenin expression to potentiate immunotherapy
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
EA201990763A1 (ru) Ингибиторы дофамин-в-гидроксилазы, проникающие через гематоэнцефалический барьер